Core Insights - Value investing focuses on identifying stocks trading below their intrinsic value, allowing investors to benefit as market prices align with true company value over time [1] - Earnings yield, calculated as earnings per share divided by stock price, is a useful metric for identifying undervalued stocks, with a higher yield indicating potential undervaluation [2][4] - A screening criterion of an earnings yield greater than 10% is established, alongside other parameters like estimated EPS growth and average daily volume [6][7] Company Highlights - IAMGOLD Corporation (IAG) is a gold exploration and mining company with projected earnings growth of 44% and 40% for 2025 and 2026, respectively, and currently holds a Zacks Rank 1 [9] - Plains GP Holdings (PAGP) is involved in crude oil and refined products transportation, with earnings growth estimates of 206% and 24% for 2025 and 2026, respectively, also holding a Zacks Rank 1 [10][11] - Hope Bancorp (HOPE) provides commercial banking services, with earnings growth estimates of 12% and 40% for 2025 and 2026, and holds a Zacks Rank 1 [12] - CommScope Holding Company, Inc. (COMM) offers communication network infrastructure solutions, with an extraordinary earnings growth estimate of 3,167% for 2025 and 28% for 2026, holding a Zacks Rank 2 [13] - Harmony Biosciences Holdings Inc. (HRMY) focuses on therapies for rare neurological disorders, with earnings growth estimates of 22% and 32% for 2025 and 2026, and holds a Zacks Rank 2 [14]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Harmony Biosciences Holdings, Inc. (HRMY) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 23.53%.For the most recent qu ...

Harmony Biosciences (HRMY) Conference July 17, 2025 10:00 AM ET Speaker0Good morning, everyone, and welcome to HC Wainwright at Home, our virtual fireside chat series. I'm Patrick Trucchio, a senior health care analyst at HCW. Today, we're joined by Jeffrey Dano, president and chief executive officer Kumar Boudur, Chief Medical and Scientific Officer Sandeep Tapadia, Chief Financial Officer and Adam Zeski, Chief Commercial Officer of Harmony Biosciences. Harmony's commercial franchise is anchored by Wakix o ...

Core Viewpoint - Investors are seeking growth stocks that can deliver above-average growth and exceptional returns, but identifying such stocks is challenging due to inherent volatility and risks [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score system aids in identifying promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - Harmony Biosciences Holdings, Inc. (HRMY) is highlighted as a recommended stock with a favorable Growth Score and a top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is crucial for investors, with double-digit growth being a strong indicator of future stock price gains [3] - Harmony Biosciences has a historical EPS growth rate of 11.7%, with projected EPS growth of 22.5% this year, surpassing the industry average of 19.1% [4] Group 3: Cash Flow Growth - High cash flow growth is essential for growth-oriented companies, allowing them to fund new projects without external financing [5] - Harmony Biosciences has a year-over-year cash flow growth of 10%, significantly higher than the industry average of -4.7% [5] - The company's annualized cash flow growth rate over the past 3-5 years is 25.7%, compared to the industry average of 4.1% [6] Group 4: Earnings Estimate Revisions - Positive trends in earnings estimate revisions correlate strongly with near-term stock price movements [7] - Current-year earnings estimates for Harmony Biosciences have been revised upward, with the Zacks Consensus Estimate increasing by 0.2% over the past month [8] Group 5: Overall Assessment - Harmony Biosciences has achieved a Growth Score of B and a Zacks Rank 2, indicating positive earnings estimate revisions and potential for outperformance [9]

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estima ...

Group 1 - Harmony Biosciences Holdings, Inc. (HRMY) shares have increased by 5.5% over the past four weeks, closing at $34.71, with a mean price target of $49.7 indicating a potential upside of 43.2% [1] - The mean estimate consists of 10 short-term price targets with a standard deviation of $11.66, where the lowest estimate is $31.00 (10.7% decline) and the highest is $70.00 (101.7% increase) [2] - Analysts show a consensus that HRMY will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for HRMY has increased by 0.2% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - HRMY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to fi ...

Financial Performance & Growth - Harmony Biosciences achieved Q1 2025 net product revenue of $184.7 million, a 20% increase compared to $154.6 million in Q1 2024[10, 59] - The company reiterates its full-year 2025 revenue guidance of $820-$860 million[12] - Harmony Biosciences has over $600 million in cash, cash equivalents, and investments[5, 58] - WAKIX net revenue grew from $160 million in 2020 to $715 million in 2024[7] Pipeline Development & Catalysts - The company anticipates multiple milestones in 2025, with 6 Phase 3 development programs expected by year-end[62] - Topline data from the Phase 3 RECONNECT study of ZYN002 in Fragile X Syndrome is expected in Q3 2025[20, 22] - Phase 3 registrational trials of Pitolisant HD in narcolepsy and idiopathic hypersomnia are scheduled to begin in Q4 2025[20, 22, 41] - Preclinical data for BP1.15205, a potential best-in-class orexin-2 agonist, will be presented at SLEEP 2025 in June[20, 22, 24] Strategic Positioning & Market Opportunity - WAKIX is considered a potential $1B+ opportunity in narcolepsy alone[8, 12, 47] - The company is pursuing utility patents for pitolisant GR and pitolisant HD, potentially extending patent protection until 2044[20] - The company aims to establish a leadership position in CNS with a potential $3B+ opportunity[64]

Harmony Biosciences (HRMY) FY 2025 Conference June 09, 2025 03:20 PM ET Speaker0 Good morning, and welcome to the Goldman Sachs Healthcare Conference. Thanks so much to the team from Harmony Biosciences for just joining us here today. And yes, I guess, we'll kick it off. I would love to get started with just maybe an overview of the company. It's changed a lot in the past, let's call it year and a half. So could you give us kind of an overview of the pipeline? Speaker1 Yes, sure, Karim. Thank you for the in ...

Financial Performance - Harmony Biosciences reported quarterly earnings of $0.78 per share, exceeding the Zacks Consensus Estimate of $0.59 per share, and up from $0.67 per share a year ago, representing an earnings surprise of 32.20% [1] - The company posted revenues of $184.73 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.66%, and an increase from $154.62 million year-over-year [2] Market Performance - Harmony Biosciences shares have declined approximately 12.9% since the beginning of the year, compared to a decline of 3.9% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.80 on revenues of $204.85 million, and for the current fiscal year, it is $2.89 on revenues of $840.82 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Harmony Biosciences belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]